It is a dual PI3K/mTOR pathway inhibitor, which inhibits proliferation in T-ALL cell lines in vitro and enhances survival in immune-deficient mice engrafted with the T-ALL cell line CCRF-CEM in vivo. This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.